DURHAM, N.C. and EXTON, Pa., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the "Company") (NASDAQ:ACGN), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Capital Market ("Nasdaq") by filing a Form 25 with the Securities and Exchange Commission (the "SEC") on or about August 15, 2023. As previously disclosed, on August 14, 2023, the Company expects to hold a special meeting seeking stockholder approval to effect a transfer and assignment of substantially all of the Company's assets to an assignee for the benefit of creditors (the "Assignment Proposal"). Subject to stockholder approval of the Assignment Proposal, and in order

DURHAM, N.C. and EXTON, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the "Company") (NASDAQ:ACGN), announced today that on May 24, 2023, the Company received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The Nasdaq notice has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Global Market. The Company has until July

DURHAM, N.C. and EXTON, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (NASDAQ:ACGN) a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the recommendation of its independent Data Monitoring Committee (DMC) in regard to the on-going TERRA Phase 2 study of ACG-701 in patients with melioidosis. The DMC is responsible for providing oversight of safety and efficacy for this study and has recommended the TERRA study continue without modification. The DMC review was a planned meeting held in order to monitor the safety of the seriously ill subjects participating in the TERRA study.  

Gainers Vistagen Therapeutics (NASDAQ:VTGN) stock rose 22.5% to $8.62 during Wednesday's after-market session. Trading volume for this security closed at 4.6 million, accounting for 394.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $68.8 million. AIM ImmunoTech (AMEX:AIM) shares rose 11.69% to $0.64. The market value of their outstanding shares is at $30.7 million. Tenon Medical (NASDAQ:TNON) shares moved upwards by 10.45% to $0.26. Tenon Medical's trading volume hit 156.5K shares by close, accounting for 23.3% of its average volume over the last 100 days. The company's market cap stands at $5.6 million. The company's, Q2 earn

Gainers Vistagen Therapeutics (NASDAQ:VTGN) shares rose 871.4% to $16.32 during Monday's regular session. Trading volume for this security as of 13:30 EST is 40.9 million, which is 18764.9% of its average full-day volume over the last 100 days. The company's market cap stands at $130.3 million. Nektar Therapeutics (NASDAQ:NKTR) shares increased by 89.89% to $1.01. The current volume of 138.1 million shares is 4109.5% of Nektar Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $191.3 million. Tabula Rasa HealthCare (NASDAQ:TRHC) stock increased by 30.84% to $10.24. Trading volume for Tabula Rasa Hea

Gainers Vistagen Therapeutics, Inc. (NASDAQ:VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints. Save Foods, Inc. (NASDAQ:SVFD) gained 140.6% to $1.54 on abnormally-high volume. Poseida Therapeutics, Inc. (NASDAQ:PSTX) jumped 53% to $2.49. Astellas and Poseida Therapeutics announced strategic investment to support Poseida's commitment to redefining cancer cell therapy. Missfresh Limited (NASDAQ:MF) shares climbed 46.5% to $2.90 on continued upward momentum after the company last week announced entry of share purchase agreements for financi

Aceragen, Inc. (NASDAQ:ACGN) shares are trading lower by 30% to $0.53 Monday morning after the company announced it will delist from the Nasdaq. The company says the delisting process will be orderly and subject to stockholder approval of the Assignment Proposal at a special meeting scheduled for August 14. The decision follows the company's plans to seek stockholder approval for a transfer and assignment of most of its assets to an assignee for the benefit of creditors, as previously disclosed. According to data from Benzinga Pro, ACGN has a 52-week high of $16.00 and a 52-week low of $0.46.

Gainers Vistagen Therapeutics (NASDAQ:VTGN) stock increased by 187.5% to $4.83 during Monday's pre-market session. The market value of their outstanding shares is at $38.5 million. Nektar Therapeutics (NASDAQ:NKTR) stock moved upwards by 33.87% to $0.71. The company's market cap stands at $134.9 million. Tabula Rasa HealthCare (NASDAQ:TRHC) stock increased by 32.05% to $10.34. The market value of their outstanding shares is at $277.6 million. The company's, Q2 earnings came out today. T2 Biosystems (NASDAQ:TTOO) stock moved upwards by 25.92% to $0.31. The market value of their outstanding shares is at $91.3 million. As per the press release, Q2 earnings came out today. Gracell Biotechno

Gainers Save Foods, Inc. (NASDAQ:SVFD) shares surged 76.6% to $1.13 in pre-market trading after gaining 15% on Friday. Missfresh Limited (NASDAQ:MF) rose 65.6% to $3.28 in pre-market trading. Missfresh shares jumped around 285% on Friday after the company announced entry of share purchase agreements for financing and business acquisition. AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) shares rose 32.5% to $0.1726 in pre-market trading after gaining around 7% on Friday. BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) gained 28.4% to $1.85 in pre-market trading after gaining over 7% on Friday. Yunji Inc. (NASDAQ:YJ) shares gained 23.8% to $1.25 in pre-market trading after falling over 7% on

Gainers Akso Health Group (NASDAQ:AHG) stock increased by 10.7% to $0.34 during Friday's after-market session. Akso Health Group's trading volume hit 54.8K shares by close, accounting for 167.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $7.7 million. T2 Biosystems (NASDAQ:TTOO) shares rose 10.08% to $0.27. T2 Biosystems's trading volume hit 35.7 million shares by close, accounting for 51.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $79.2 million. MSP Recovery (NASDAQ:LIFW) shares rose 9.5% to $0.16. The company's market cap stands at $54.5 million. Context Therapeutics (NASDAQ:CN

Aceragen, Inc. (the "Company") (NASDAQ:ACGN), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Capital Market ("Nasdaq") by filing a Form 25 with the Securities and Exchange Commission (the "SEC") on or about August 15, 2023. As previously disclosed, on August 14, 2023, the Company expects to hold a special meeting seeking stockholder approval to effect a transfer and assignment of substantially all of the Company's assets to an assignee for the benefit of creditors (the "Assignment Proposal"). Subject to stockholder approval of the Assignment Proposal, and in order to ensure an orderly delisting process, the Company has determin